Diagnostic and Prognostic keys in Oral Diffuse Large B cell Lymphoma

Objectives: 1. To sub-classify the DLBCL into Double Expresser Lymphoma phenotype using the expression levels of MYC and BCL2 proteins.
2. To correlate the clinico-pathological parameters and the expression levels of MYC/BCL2 levels with the Disease-Specific Survival of DLBCL patients.
3. To investigate the dependant and independent survival prediction of the clinicopathological parameters and the expression levels of MYC and BCL2 proteins in DLBCL.
Methods: A retrospective analytical study, 151 patients. (2013 and 2018). FFPE Blocks, Immunohistochemistry, Quantification of IHC stained sections, the positively stained cells were graded as 0, 1, 2, 3, and 4.
Inclusion Criteria: A) Aged 16 years and above. B) Diagnosed with DLBCL that fits the WHO- ICD10 classification. C) Have not received any surgical treatment, chemotherapy, or radiotherapy before specimen collection. D) Had to have adequate tissue material in their FFPE block. E) Have signed an informed consent

Exclusion Criteria: A) Patients' files with insufficient or inconsistent medical data or mismatched tissue blocks. B) Individuals under 16 years . C) Patients who sought treatment in private clinics. D) Records of HIV or Hepatitis B surface antigen-positive patients or were under medication were also excluded.
Results: 65% of the samples were females. The mean age was 57.25 years. 46% were stage IV at the time of diagnosis. 83% of the samples had concurrent high expression rate of MYC and BCL2. The highest tumor site was cervical Lymph nodes. 55% passed on of this malignancy.
Conclusions: Determining the diagnostic and prognostic potential of MYC and BCL2 biomarkers could serve as the foundation for developing a valuable tool for patient classification and target-based treatment.